Company intelligence / Profile preview

Neutec Pharmaceuticals

Istanbul, Turkeybacnetinternational.org ↗

Ownership: Private
Development stage: Commercial

Overview

Mycograb received orphan drug status in EU and US; both Mycograb and Aurograb were late-stage assets at time of Novartis acquisition.[1][6] The Turkish entity has a large portfolio of branded generics and respiratory products but does not publicly disclose clinical trial results.

Therapeutic areas: PulmonologyOncologyInfectious DiseasesGastroenterologyWomen's Health
Modalities: Small moleculesInhaled therapeutics/dry powder inhalersBranded generics and value-added genericsRecombinant antibodies ("grabs")
Industry: Biotech

Drug pipeline

3 assets

efungumab

2 more assets in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company Limited

Beyond the preview

Go deeper on Neutec Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neutec Pharmaceuticals.

Explore the full profile